Our studies suggested that high VEGFR-2 expression is associated with poor prognosis in NSCLC patients, and we also studied single- and double-mutant NSCLC cell lines to provide a new outlook on ways to overcome EGFR-TKI resistance in NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.